Mayne Pharma secures IMVEXXY® patent runway to 2032 with Sun Pharma settlement
Mayne Pharma Group Limited (ASX: MYX) has resolved US Paragraph IV patent litigation with Sun Pharmaceutical Industries Ltd (Sun Pharma) over IMVEXXY® (estradiol vaginal inserts), originally commenced in July 2024. The settlement establishes an agreed generic market entry date of 21 October 2032, or earlier under certain circumstances, subject to court approval. No financial payment or upfront monetary consideration was exchanged between the parties. The outcome provides long-term commercial runway for a product that generated US$29.3M in net sales, with the final patent expiring in February 2034.
When big ASX news breaks, our subscribers know first
What the settlement means for IMVEXXY®
Under the terms of the settlement, Sun Pharma has agreed to a potential generic entry date of 21 October 2032, or earlier under certain circumstances, preserving Mayne Pharma’s exclusivity window for the product. Importantly, one further Paragraph IV litigation matter for IMVEXXY® remains ongoing, meaning this settlement does not represent a complete resolution of all IP disputes relating to the product.
The announcement notes the settlement “highlights the validity and enforceability of the IMVEXXY® patent portfolio,” framing the outcome as an affirmation of the underlying IP position. With the last expiring patent running to February 2034, the agreed 2032 entry date preserves full exclusivity before patent expiry.
Aaron Gray, Chief Executive Officer
“Resolving the Paragraph IV litigation with Sun Pharma is an important step in protecting the value of IMVEXXY®. The agreed pathway strengthens our longer term planning for IMVEXXY® within our menopause portfolio as part of our overall Women’s Health business. We will continue to actively manage and defend our IP estate and execute on access and patient support initiatives to maximise the product’s patent life and long-term contribution.”
Understanding Paragraph IV litigation — what investors need to know
Paragraph IV litigation arises from the US Hatch-Waxman framework, which allows generic manufacturers to seek regulatory approval to market a generic version of a branded medicine before its patents expire. To do so, the manufacturer files an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA), including a Paragraph IV certification. That certification alleges that one or more Orange Book-listed patents for the branded product are invalid, unenforceable, or not infringed.
The process follows a defined sequence:
- The generic manufacturer files an ANDA with a Paragraph IV certification
- The brand company must respond within 45 days to trigger an automatic stay
- The stay delays FDA final approval of the ANDA for up to 30 months, subject to applicable circumstances, or until the dispute is resolved
- The dispute resolves via a litigation outcome or settlement
For investors, settling with a defined entry date is generally preferable to extended litigation. It removes uncertainty around the timing of potential generic competition, enables more confident long-term revenue planning, and avoids the unpredictability of court outcomes. In this instance, Mayne Pharma and TherapeuticsMD brought the original proceedings jointly against Sun Pharma, and the agreed 2032 entry date provides a clear planning horizon.
IMVEXXY® performance and the Women’s Health growth story
In the 12 months to 30 June 2026, IMVEXXY® delivered total prescription growth of 6% over the prior corresponding period, with net sales rising 8% to US$29.3M. The product sits within Mayne Pharma’s Women’s Health franchise and is supported by ongoing commercial execution focused on access, adherence, and prescriber engagement.
IMVEXXY® is a locally administered estradiol vaginal insert indicated for the treatment of moderate to severe dyspareunia due to menopause. Key facts for investor reference:
The IMVEXXY safety profile received further support earlier in 2026, when a post-marketing study across 9.5 million postmenopausal women found no increased risk of endometrial cancer, a finding consistent with the FDA’s subsequent move to remove box warnings from the product’s prescribing information.
- Indication: Moderate to severe dyspareunia due to menopause
- Net sales (12 months to 30 June 2026): US$29.3M (+8% year-on-year)
- Prescription growth (12 months to 30 June 2026): +6% year-on-year
- Agreed generic entry date (Sun Pharma): 21 October 2032
- Last patent expiry: February 2034
| Event | Date | Significance |
|---|---|---|
| Paragraph IV litigation commenced | July 2024 | Patent litigation with Sun Pharma commenced |
| Settlement agreed | 30 September 2026 | Parties resolved litigation; no financial consideration exchanged; subject to court approval |
| Agreed generic entry date (Sun Pharma) | 21 October 2032 | Preserves Mayne Pharma exclusivity; last patent expires February 2034 |
Investment thesis — IP clarity as a long-term value anchor
The settlement reduces headline litigation risk from Sun Pharma and enables more confident long-term planning for a product that contributes meaningfully to Mayne Pharma’s revenue base. With an agreed generic entry pathway for October 2032 (subject to certain circumstances), the company retains a protected runway from the date of settlement.
Investors should note that one further Paragraph IV litigation matter for IMVEXXY® remains active, keeping the IP management story ongoing. Mayne Pharma has stated its intention to continue actively managing and defending its IP estate, alongside patient support and access initiatives, with the aim of maximising the product’s patent life and long-term commercial contribution.
The IMVEXXY settlement is one of several active legal matters shaping Mayne Pharma’s near-term balance sheet; the Cosette litigation outcome resulted in a confirmed $14.4 million cash recovery in June 2026 following the NSW Supreme Court cost order, demonstrating the company’s capacity to enforce its legal positions across different dispute types.
Stay Ahead on ASX Healthcare News
Big News Blast delivers FREE breaking ASX healthcare alerts to your inbox within minutes of release, complete with in-depth analysis already done. Join 20,000+ investors who never miss a market-moving announcement. Click the “Free Alerts” button at StockWire X to get started today.